Review3 Biotech2019
Recent systems biology approaches for probiotics use in health aspects: a review.
Review in 3 Biotech, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 25 citations in OpenAlex.
- Exploring the Multifaceted Therapeutic Potential of Probiotics: A Review of Current Insights and Applications.Probiotics and antimicrobial proteins · 2025Review
- Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics.Frontiers in microbiology · 2023Review
- Pro-biomics: Omics Technologies To Unravel the Role of Probiotics in Health and Disease.Advances in nutrition (Bethesda, Md.) · 2021Review
- The role of the microbiome in gastrointestinal inflammation.Bioscience reports · 2021Article
- Probiotic3 Biotech · 2021Article
- EngineeredExperimental and therapeutic medicine · 2020Review
- Promising discovery of beneficial3 Biotech · 2020Article
- Probiotics and MicroRNA: Their Roles in the Host-Microbe Interactions.Frontiers in microbiology · 2020Review
- Isolation of aFrontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The market of probiotics is growing dynamically for the food and supplements, which provides better health to an individual. Probiotics are used as dietary management for diseases, but it varies between regions and persons. Systems biology can help in resolving the strain specificity of probiotics by studying their genome level organization. In this review, we have compiled facets of systems biology and next-generation omics methods such as metagenomics, proteomics and metabolomics. These tools are crucial for the optimization of the metabolic processes in probiotics and hence, their use for human health. The limitations and challenges associated with the development of probiotics involve their stability and function in different individuals. Systems biology facilitates emerging metabolic engineering approaches to improve probiotics strain for their broader application. This review provides comprehensive and updated knowledge of engineered probiotics as therapeutics and various challenges in the development of engineered probiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.